Biomarkers and Treatment Strategies for Breast Cancer Recurrence

被引:7
作者
Rajput, Shivam [1 ]
Sharma, Pramod Kumar [1 ]
Malviya, Rishabha [1 ]
机构
[1] Galgotias Univ, Sch Med & Allied Sci, Dept Pharm, Greater Noida, Uttar Pradesh, India
关键词
Breast cancer; resistance; recurrence; cancer; biomarkers; targeted therapy; EPITHELIAL-MESENCHYMAL TRANSITION; CIRCULATING TUMOR-CELLS; PHASE-III TRIAL; STEM-CELLS; TRANSCRIPTIONAL REPRESSOR; PLUS CAPECITABINE; INITIATING CELLS; DRUG-RESISTANCE; BONE-MARROW; BISPHOSPHONATES;
D O I
10.2174/0113894501258059231103072025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite recent treatment advancements, breast cancer remains a life-threatening disease. Although treatment is successful in the early stages, a significant proportion of individuals with breast cancer eventually experience a recurrence of the disease. Breast tumour recurrence poses a significant medical issue. Despite tumours being a primary cause of mortality, there remains a limited understanding of the fundamental mechanisms underlying tumour recurrence. The majority of the time, after surgery or medical treatment, this metastatic disease manifests itself after the disease is undiagnosed for a considerable amount of time. This phenomenon is commonly referred to as a relapse or recurrence. Metastatic breast cancer has the potential to recur at varying intervals, ranging from a few months to several decades following the initial diagnosis and treatment. This article aimed to summarise the primary causes of breast cancer recurrence and highlight the key issues that need to be addressed in order to effectively decrease the mortality rate among breast cancer patients. This article discusses various therapeutic approaches currently employed and emerging treatment strategies that hold the potential for the complete cure of cancer.
引用
收藏
页码:1209 / 1220
页数:12
相关论文
共 104 条
  • [1] Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel
    Aapro, M.
    Abrahamsson, P. A.
    Body, J. J.
    Coleman, R. E.
    Colomer, R.
    Costa, L.
    Crino, L.
    Dirix, L.
    Gnant, M.
    Gralow, J.
    Hadji, P.
    Hortobagyi, G. N.
    Jonat, W.
    Lipton, A.
    Monnier, A.
    Paterson, A. H. G.
    Rizzoli, R.
    Saad, F.
    Thuerlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (03) : 420 - 432
  • [2] Ahmad A., 2012, DNA Repair of Cancer Stem Cells, P33, DOI [10.1007/978-94-007-4590-2_3, DOI 10.1007/978-94-007-4590-2_3]
  • [3] RETRACTED: Down-Regulation of uPA and uPAR by 3,3′-Diindolylmethane Contributes to the Inhibition of Cell Growth and Migration of Breast Cancer Cells (Retracted article. See vol. 117, pg. 1959, 2016)
    Ahmad, Aamir
    Kong, Dejuan
    Wang, Zhiwei
    Sarkar, Sanila. H.
    Banerjee, Sanjeev
    Sarkar, Fazlul H.
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2009, 108 (04) : 916 - 925
  • [4] NOTCH SIGNALING
    ARTAVANISTSAKONAS, S
    MATSUNO, K
    FORTINI, ME
    [J]. SCIENCE, 1995, 268 (5208) : 225 - 232
  • [5] β1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence
    Barkan, Dalit
    Chambers, Ann F.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (23) : 7219 - 7223
  • [6] Metastatic Growth from Dormant Cells Induced by a Col-I-Enriched Fibrotic Environment
    Barkan, Dalit
    El Touny, Lara H.
    Michalowski, Aleksandra M.
    Smith, Jane Ann
    Chu, Isabel
    Davis, Anne Sally
    Webster, Joshua D.
    Hoover, Shelley
    Simpson, R. Mark
    Gauldie, Jack
    Green, Jeffrey E.
    [J]. CANCER RESEARCH, 2010, 70 (14) : 5706 - 5716
  • [7] Exploring the role of cancer stem cells in radioresistance
    Baumann, Michael
    Krause, Mechthild
    Hill, Richard
    [J]. NATURE REVIEWS CANCER, 2008, 8 (07) : 545 - 554
  • [8] Blum JL, 2004, ANN ONCOL, V15, P30
  • [9] Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
    Blum, JL
    Jones, SE
    Buzdar, AU
    LoRusso, PM
    Kuter, I
    Vogel, C
    Osterwalder, B
    Burger, HU
    Brown, CS
    Griffin, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 485 - 493
  • [10] Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
    Bonneterre, J
    Roché, H
    Monnier, A
    Guastalla, JP
    Namer, M
    Fargeot, P
    Assadourian, S
    [J]. BRITISH JOURNAL OF CANCER, 2002, 87 (11) : 1210 - 1215